Sandra Horning, MD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of obinutuzumab (Gazyvaro, EU; Gazyva, US) in the frontline setting for the treatment of patients with follicular lymphoma, according to Roche, the manufacturer of the treatment.
Obinutuzumab is currently approved in the United States and EU for use in combination with bendamustine for patients with certain types of previously treated follicular lymphoma.
Shah, NN, Stetler-Stevenson M, Yuan CM, et al. Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Presented at: 58th ASH Annual Meeting and Exposition; San Diego, California; December 2-6, 2016. Abstract 650.
... to read the full story